OVERVIEW
We offer multi-faceted and holistic advice to our clients in this sector – encompassing both representing clients in connection with investments and M&A transaction in this space and also advising them on complex regulatory and structuring issues that are specific to pharmaceuticals and life sciences sector. This enables us to enable our clients in scaling their operations whether it be through M&As or through facilitating innovative strategies for organic growth. Specifically, we have supported clients in this space in relation to issues concerning exchange control, drug price control, safety and efficacy issues, regulations for drugs and cosmetics, clinical trials etc. We also extensive experience in representing clients before regulatory authorities such as the Reserve Bank of India, Securities and Exchange Board of India and Department of Pharmaceuticals on several complex matters and seeking regulatory approvals.
Our clientele includes numerous global players within this sector, encompassing market leading pharmaceutical companies, biotechnology companies, telemedicine providers, medical equipment manufacturers etc. while also including numerous prominent private equity firms that have invested in the Indian pharmaceuticals business.
To provide comprehensive legal services to our clients, we work closely with our Corporate and M&A team, Regulatory team, Insolvency & Restructuring Team, Private Equity team, Capital Markets team, Competition team, and Disputes team. This collaborative approach ensures that our clients receive integrated support throughout their projects or transactions.
Contact us today to learn more about how we can assist you.
KEY PARTNERS
-
Advised Viatris (formerly, Mylan) in the sale of its global biosimilar business to Biocon Biologics (a subsidiary of Biocon) for USD 3.335 billion. This deal is the largest M&A deal in India in biosimilars business and one of the largest M&A deals in India in pharmaceutical space. Awards: (i) M&A Deal of the Year (Premium) at the Asian Legal Business (ALB) India Law Awards 2023; and (ii) India Business Law Journal (IBLJ) Deal of the Year 2022.
-
Advised Ranbaxy Laboratories in relation to merger with Sun Pharmaceutical in a deal valued at USD 3.2 billion. Awards: (i) India Business Law Journal - ‘Dealmaker of the year 2014’; (ii) SIAN-MENA COUNSEL Deals of the Year; and (iii) The Asian Lawyer 2015 M&A Deal of the Year: South & Southeast Asia
-
Advised Abbott Laboratories in relation to its US$ 6.2 billion acquisition of Belgium-based Solvay Pharmaceutical.
-
Advised Viatris (formerly, Mylan) in relation to acquisition of the Upjohn business from Pfizer’s Indian subsidiaries, as part of a global combination of Upjohn Inc., a subsidiary of Pfizer Inc., with Mylan N.V., in a US$ 12 billion deal, leading to creation of a new global pharmaceutical company, Viatris Inc.
-
Advised Baxter International in acquisition of Claris Injectables India and simultaneously purchase of the overseas injectables business of the Claris group, in a deal valued at US$ 625 million. Recognition: The Prime Minister’s Office wrote to us acknowledging the significance of this deal and viewed Baxter as an important stakeholder for the progress and growth of the Indian pharmaceutical industry.
-
Advised Carlyle Group in structuring and setting up of a one-of-its-kind integrated pharmaceutical platform through Viyash Life Sciences Private Limited, and in this regard advised in certain acquisitions in the pharmaceutical space along with (i) 100% acquisition of Symed Labs Limited; and (ii) acquisition of majority stake in Appco Pharma LLC – both for undisclosed amounts.